: iStockAnalyst.com Symbols Feed

Buy 'Low-Density'… How To Take The Guesswork Out Of Valuing Stocks

Wed, 26 Aug 2009 13:32:48 GMT

I don’t care what investing legend you idolize and try to emulate – Buffett, Graham, Rogers, Lynch – they all share a common recommendation. Always buy undervalued stocks and sell them when they’re overvalued. Or more commonly: “Buy low, sell high.” Of course, if you’ve invested for more than a week, you know this is easier said than done.[More...]

Healthcare Product And Supplies, Short And Long Term Outlook

Mon, 06 Apr 2009 07:54:00 GMT

Healthcare Products and Supplies is a unique sub sector of healthcare that holds the potential for great growth opportunities in the coming years. The sub sector is extremely vast, with companies providing products and supplies to a variety of medical areas such as cosmetic surgery, eye care, cardiology, orthopedics, and diabetes to list just a few. Within these major areas, HCP&S ’s products are further divided into higher tech products such as drug eluting stents (DESs) and lower tech products such as hypodermic needles and scalpels. In[More...]

Deep Value Plays

Mon, 16 Feb 2009 03:42:00 GMT

As S&P 500 earnings have started their collapse (see articles here and here), there has been a debate about whether this market constitutes good value. From a bottom up basis, however, I am seeing values that I haven’t seen in a long time. Screening on net-net working capital Using the free data from the Yahoo! finance website, I wrote a program that screened an investment universe that is roughly equivalent to the Russell 3000 members. The test is: stocks that trade below net-net working capital (current assets less all liabilities and preferred) and has positive trailing 12 month earnings. The net-net working capital requirement is a classic[More...]

Earnings Preview for Feb 9-13 - Earnings Preview

Fri, 06 Feb 2009 18:52:00 GMT

Activision Blizzard Inc. (ATVI) could top expectations. IntercontinentalExchange, Inc. (ICE) and Terex Corporation (TEX) could miss. Though nearly 400 companies are scheduled to report, traders are going to keep a close eye on Washington. Treasury Secretary Timothy Geithner will announce a revised bank bailout plan on Monday. This plan could include the creation of a bad bank to absorb distressed debts (what TARP was[More...]

In Search of Healthcare Diamonds In The Rough

Mon, 12 Jan 2009 04:52:00 GMT

While we are not even halfway through January, the healthcare sector is already active with deal-making, ranging from the rumored $95 buyout of biotech giant Genetech (DNA) by Roche (RHHBY) to Endo's (ENDP) purchase of small-cap, specialty pharma Indevus (IDEV) to Sequenom's (SQNM) $41M offer for emerging diagnostic company EXACT Sciences (EXAS) – which was promptly rebuffed by EXACT's board after the market close on Monday on the promise of a better deal in the works for shareholders. Larger bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, and drug discovery technology platforms given the huge declines in the stock prices of small/micro-cap stocks in the healthcare sector. With that in mind, I sorted through the ETF Innovators indexes for a list of a dozen[More...]

Buffett To The Rescue

Tue, 12 Feb 2008 13:38:15 GMT

Good morning. Much like yesterday, we have a positive bias to start out the day but few notable headlines to work with. News that Warren Buffet has offered to reinsure several municipal bond insureres and that six mortgage...[More...]

Mixed News & Poor Sentiment

Thu, 13 Dec 2007 14:18:06 GMT

Good morning. We're set for lower market this morning as weakness in global markets weigh heavily on sentiment. For the most part, investors are sorting through some mixed news. While we have a better than expected report form Lehman Brothers (LEH) and strong report on retail sales, a hotter than expected [More...]

Sell the Gap

Wed, 12 Dec 2007 18:58:08 GMT

Markets have gone straight south since the open and support levels have been taken out yet again. The DJIA +50, NAZ +23 and SPX +10. Sector...[More...]

Cynosure (NASDAQ:CYNO): We would be agressive buyers at current levels - Jeffco

Mon, 12 Nov 2007 15:41:43 GMT

- Jefferies is out with a nice call on Cynosure (NASDAQ:CYNO) this AM, reiterating their Buy rating and $60 tgt saying they would be agressive buyers at current levels.Firm notes CYNO shares have declined ~20% since the company reported impressive 3Q results on unwarranted fears associated with a deceleration in the aesthetic laser market....[More...]

CLOSING NUMBERS - Nov 6 2007 5:01PM

Tue, 06 Nov 2007 20:55:44 GMT

Nice gains in the closing hour gets the SPX past the 50 day SMA at the 1,520 area with sights set on the 1,535/1,540 level and the 50% retracement between 1,576 and 1,490.Strong sectors -metals, emerging markets, oils, insurance, banks and homies while airlines, internets, utils and biotechs lagged.[More...]

Cynosure Reports Second Quarter 2009 Financial Results

Tue, 28 Jul 2009 12:02:00 GMT

Cynosure, Inc. , a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three months ended June 30, 2009.[More...]

Cynosure To Announce Second-Quarter 2009 Financial Results On July 28

Wed, 15 Jul 2009 12:26:00 GMT

Cynosure, Inc. , a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that the company will host its second-quarter 2009 conference call on Tuesday, July 28, 2009 at 9:00 a.m. ET.On the call, President and Chief Executive Officer Michael Davin and Executive Vice President and Chief Financial Officer Timothy Baker will discuss Cynosure's financial results, as well as the company's business outlook and strategy.Those who wish to listen to the conference call webcast should visit the 'Investor Relations' section of the company's website at www.cynosure.com. The live call also can be accessed by dialing 407-5790 or 689-8328. If you are unable to listen to the live call, the webcast will be archived on the company's website. About Cynosure, Inc.Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com. Contact[More...]

Cynosure Signs Agreement with Unilever to Develop Light-Based Devices for Home Use

Wed, 01 Jul 2009 12:26:00 GMT

Partnership Combines Unilever's Consumer Goods Expertise with Cynosure's Strength as a Leading Developer of Light-Based Technology[More...]

Gabelli & Company, Inc.’s Healthcare Symposium

Wed, 03 Jun 2009 12:00:00 GMT

Gabelli & Company, Inc. will host a Healthcare Symposium on Tuesday, June 9, 2009 at the Sofitel New York. This investment research meeting will include presentations from senior management of various dental, dermatology, and specialty healthcare manufacturers and distributors. Institutional investors should contact their salesperson for more information or to register.[More...]

Cynosure Announces Presentations at Upcoming Investor Conferences

Tue, 02 Jun 2009 12:25:00 GMT

Cynosure, Inc. , a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that President and Chief Executive Officer Michael Davin and Chief Financial Officer Timothy Baker are scheduled to present at the following investor conferences in New York City this month:[More...]

Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing

Wed, 13 May 2009 12:26:00 GMT

Company's New Smartlipo MPX 46 Watts Enables Physicians to Melt and Remove Larger Areas of Fat 50% Faster, with Superior Patient Safety[More...]

Cynosure Reports Financial Results for the First Quarter of 2009

Tue, 05 May 2009 15:59:00 GMT

First Quarter 2009 Financial Results
Consistent with Cynosure's April 15 announcement, revenues for the three months ended March 31, 2009 were $14.8 million, reflecting the continued effects of the global economic recession and the continued restrictive credit environment in the aesthetic laser industry.
Cynosure's net loss for the first quarter of 2009 was $4.0 million, or $0.32 per share, consistent with the anticipated loss range of $3.8 million to $4.3 million the company announced on April 15.

[More...]

Cynosure Announces Preliminary Financial Results for the First Quarter of 2009

Wed, 15 Apr 2009 13:48:00 GMT

Company Further Reduces 2009 Operating Expenses to Address Continued Industry Weakness;
WESTFORD, Mass., April 15 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced preliminary, unaudited financial results for the quarter ended March 31, 2009.
"The global economic recession continued to negatively affect our business throughout the first quarter, which historically has been our weakest quarter of the year," said Cynosure President and Chief Executive Officer Michael Davin.

[More...]